Bayer HealthCare, a Germany Headquarter Chemical Company, is buying Teva Pharmaceuticals, a US-based animal health business, for USD 60 million up front, plus up to USD 85 million in manufacturing and sales milestones. Bayer HealthCare maintains taking on Teva’s the animal health operation will allow the expansion of its companion (pet food) and food animal product lines in the U.S., including the introduction of anti-infective and reproductive hormones. The Teva business will be integrated into Bayer’s own animal health business.
Featured News
Sullivan & Cromwell Names New Antitrust Co-Head
Nov 1, 2026 by
CPI
Danish Furniture Brand Hübsch Fined €670,000 in Price-Fixing Case
Nov 1, 2026 by
CPI
UK Court Backs Ofcom in Legal Battle With Meta, TikTok and X
Nov 1, 2026 by
CPI
House Democrat Targets Trump’s Antitrust Settlements With New Oversight Bill
Nov 1, 2026 by
CPI
Vail Resorts, Alterra Seek Dismissal of Ski Price-Fixing Suit, Deny Collusion Claims
Nov 1, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Exclusive Dealing
Oct 25, 2026 by
CPI
Exclusive Dealing Without Exclusivity: Screening Contracts, Loyalty Rebates, and the Limits of Antitrust Tests
Oct 25, 2026 by
David Martimort & Jérôme Pouyet
When Competition for Exclusivity Raises Prices: Rebates, Pricing Rules, and the Insulin Puzzle
Oct 25, 2026 by
Daniel P. O’Brien & Greg Shaffer
Why Leaving the Door Open Can Be (Much) Worse Than Closing It: Share-Based Requirements, Buyer-Specific Costs, and Foreclosure
Oct 25, 2026 by
Zhijun Chen & Greg Shaffer
Antitrust Chronicle® – EU Merger Guidelines
Oct 19, 2026 by
CPI